Sinovac secures $515 million to boost COVID-19 vaccine production
SHANGHAI (Reuters) - China's Sinovac Biotech has secured $515 million in funding from a local firm to double production capacity of its coronavirus vaccine, the companies said on Monday, as it expects efficacy data of its experimental shot this month. The investment deal also comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.
COVID-19 vaccine production" src="https://images.firstpost.com/wp-content/uploads/reuters/12-2020/07/2020-12-06T233722Z_1_LYNXMPEGB50M6_RTROPTP_2_HEALTH-CORONAVIRUS-BRAZIL-SINOVAC.jpg" alt="Sinovac secures 515 million to boost COVID19 vaccine production" width="300" height="225" />
SHANGHAI (Reuters) - China's Sinovac Biotech
The investment deal also comes as Sinovac expands supply deals and trials of its experimental COVID-19 vaccine CoronaVac with more countries following positive results from early to mid-stage clinical trials.
China's Sino Biopharmaceutical Limited <1177.HK> said on Monday a business unit will invest $515 million in Sinovac Life Sciences, a subsidiary of Sinovac, to help development and production of CoronaVac.
The investment will give Sino Biopharmaceutical a 15.03% interest in Sinovac Life Sciences, Sino Biopharmaceutical said in a filing to the Hong Kong Stock Exchange.
Sinovac said in a separate statement that it would be able to manufacture 300 million vaccine doses annually and aims to complete construction of a second production facility by the end of 2020 to increase annual COVID-19 vaccine production capacity to 600 million doses.
Depending on market conditions and the availability of financing, it may seek to further expand its production capacity, Sinovac said.
Sinovac has secured CoronaVac supply deals with several countries including Indonesia, Turkey, Brazil and Chile, and is holding talks with the Philippines for a potential sale.
CoronaVac is also one of three experimental COVID-19 vaccines China has been using to inoculate around 1 million people under an emergency use programme.
Brazil's Butantan Institute biomedical centre, which is running a Phase 3 trial of CoronaVac in the country, said last week that Sinovac was expected to publish efficacy results from its vaccine trials by Dec. 15.
(Reporting by Andrew Galbraith; Editing by Sam Holmes)
This story has not been edited by Firstpost staff and is generated by auto-feed.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
By William James LONDON (Reuters) -British Prime Minister Boris Johnson said on Sunday tougher lockdown restrictions were probably on the way as COVID-19 cases keep rising, but that schools were safe and children should continue to attend where permitted. COVID-19 cases in Britain are at record levels and the increase in numbers is fuelled by a new and more transmissible variant of the virus
By Maher Nazeh BAGHDAD (Reuters) - Tens of thousands of supporters of Iranian-backed Iraqi paramilitary groups chanted anti-American slogans in central Baghdad on Sunday to mark the anniversary of the U.S. killing of Iranian general Qassem Soleimani and an Iraqi militia commander.
By Nathan Layne and Joseph Ax CUTHBERT, Ga. (Reuters) -Control of the U.S. Senate – and with it, the likely fate of President-elect Joe Biden's legislative agenda – will be on the ballot on Tuesday when voters in Georgia decide twin runoff elections